Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective dosesReportar como inadecuado




Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Radiation Oncology

, Volume 4, Issue 1, pp 65–70

First Online: 10 December 2014Received: 29 May 2014Accepted: 13 November 2014DOI: 10.1007-s13566-014-0175-2

Cite this article as: Patel, N.R., Lanciano, R., Sura, K. et al. J Radiat Oncol 2015 4: 65. doi:10.1007-s13566-014-0175-2

Abstract

ObjectiveFew studies have evaluated re-irradiation of lung cancer recurrences with stereotactic body radiotherapy SBRT. This study evaluates outcomes with SBRT re-irradiation for recurrent lung cancer.

MethodsTwo hundred and seventy-eight patients treated with SBRT for lung cancer were retrospectively reviewed. Of those, 26 patients with 29 tumors were re-irradiated with SBRT. Ninety percent of tumors received prior external beam irradiation and 10 % received prior SBRT. Previous median radiation dose was 61.2 Gy with a median 8-month interval from previous radiation. The median re-irradiation SBRT dose was 30 Gy 48 Gy10 biological effective dose BED. Endpoints evaluated included local control, overall survival, and progression-free survival.

ResultsTwenty-five of 29 tumors were evaluable for local control, with 27 tumors 93 % considered in-field recurrences. In-field crude local control rate was 80 % 20-25 with 1 and 2-year actuarial rates of 78.6 and 65.5 %, respectively. One and 2-year actuarial survival rates were 52.3 and 37.0 %, respectively. One and 2-year actuarial progression-free survival rates were 56.7 and 37.0 %, respectively. Fifty-five percent of patients reported acute-chronic grades 1 and 2 toxicities. No grade 3 or higher toxicities were reported.

ConclusionPatients with recurrent lung cancer have limited options. SBRT re-irradiation is tolerable even after a median 61.2 Gy to the re-irradiation site. The lower BED used provided acceptable progression-free survival with low toxicity. Given the poor prognosis with current treatment options, new paradigms for re-treatment should include SBRT-re-irradiation as an adjunct to systemic therapy for in-field lung cancer recurrence.

KeywordsSBRT Re-irradiation Lung cancer Recurrence Radiation  Download fulltext PDF



Autor: Nisha R. Patel - Rachelle Lanciano - Karna Sura - Jun Yang - John Lamond - Jing Feng - Michael Good - Ed J. Gracely - Ly

Fuente: https://link.springer.com/



DESCARGAR PDF




Documentos relacionados